C-reactive protein induces p53-mediated cell cycle arrest in H9c2 cardiac myocytes

Biochemical and Biophysical Research Communications

Volumn 410, Issue 3, 2011, Pages 525-530

  Choi, Ji Won ^a   Lee, Kyung Hye ^a,b   Kim, Soo Hyuk ^a,b   Jin, Taewon ^a,b   Lee, Beom Seob ^a   Oh, Jaewon ^a,c   Won, Ho Yeon ^a,c   Kim, Soo Young ^a,c   Kang, Seok Min ^a,b,c,d   Chung, Ji Hyung ^a,b,d  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University Health System   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

C reactive protein; Cardiac cells; Cell cycle; ERK1 2; Fc RIIIa; P53

Indexed keywords

C REACTIVE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21; PROTEIN P53; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEART MUSCLE CELL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

C-REACTIVE PROTEIN; CELL CYCLE; CELL LINE; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; PHOSPHORYLATION; RECEPTORS, IGG; RNA, SMALL INTERFERING; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960049145     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.016     Document Type: Article

References (36)

1. Gortney J.S., Sanders R.M. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am. J. Health Syst. Pharm. 2007, 64:2009-2016.
2. Bisoendial R.J., Boekholdt S.M., Vergeer M., Stroes E.S., Kastelein J.J. C-reactive protein is a mediator of cardiovascular disease. Eur. Heart J. 2010, 31:2087-2091.
3. Wilson A.M., Ryan M.C., Boyle A.J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int. J. Cardiol. 2006, 106:291-297.
4. Bisoendial R.J., Kastelein J.J., Stroes E.S. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007, 195:e10-e18.
5. Baldassarre D., De Jong A., Amato M., Werba J.P., Castelnuovo S., Frigerio B., Veglia F., Tremoli E., Sirtori C.R. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann. Med. 2008, 40:21-44.
6. Suh W., Kim K.L., Choi J.H., Lee Y.S., Lee J.Y., Kim J.M., Jang H.S., Shin I.S., Lee J.S., Byun J., Jeon E.S., Kim D.K. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem. Biophys. Res. Commun. 2004, 321:65-71.
7. Verma S., Kuliszewski M.A., Li S.H., Szmitko P.E., Zucco L., Wang C.H., Badiwala M.V., Mickle D.A., Weisel R.D., Fedak P.W., Stewart D.J., Kutryk M.J. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004, 109:2058-2067.
8. Devaraj S., Davis B., Simon S.I., Jialal I. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1170-H1176.
9. Ørn S., Manhenke C., Ueland T., Damås J.K., Mollnes T.E., Edvardsen T., Aukrust P., Dickstein K. C-reactive protein infarct size, microvascular obstruction, and left-ventricular remodeling following acute myocardial infarction. Eur. Heart J. 2009, 30:1180-1186.
10. Arruda-Olson A.M., Enriquez-Sarano M., Bursi F., Weston S.A., Jaffe A.S., Killian J.M., Roger V.L. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am. J. Cardiol. 2010, 105:917-921.
11. Nagai T., Anzai T., Kaneko H., Mano Y., Anzai A., Maekawa Y., Takahashi T., Meguro T., Yoshikawa T., Fukuda K. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 2011, 57:208-215.
12. Zhang R., Zhang Y.Y., Huang X.R., Wu Y., Chung A.C., Wu E.X., Szalai A.J., Wong B.C., Lau C.P., Lan H.Y. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010, 55:953-960.
13. Yang J., Wang J., Zhu S., Chen X., Wu H., Yang D., Zhang J. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol. Cell Biochem. 2008, 310:215-226.
14. Ikeda U., Maeda Y., Yamamoto K., Shimada K. C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc. Res. 2002, 56:86-92.
15. Venkatakrishnan C.D., Dunsmore K., Wong H., Roy S., Sen C.K., Wani A., Zweier J.L., Ilangovan G. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1736-H1744.
16. Oyama K., Takahashi K., Sakurai K. Hydrogen peroxide induces cell cycle arrest in cardiomyoblast h9c2 cells, which is related to hypertrophy. Biol. Pharm. Bull. 2011, 34:501-506.
17. Kuribayashi K., El-Deiry W.S. Regulation of programmed cell death by the p53 pathway. Adv. Exp. Med. Biol. 2008, 615:201-221.
18. Lavin M.F., Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006, 13:941-950.
19. Fujii H., Li S.H., Szmitko P.E., Fedak P.W., Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2476-2482.
20. Hanriot D., Bello G., Ropars A., Seguin-Devaux C., Poitevin G., Grosjean S., Latger-Cannard V., Devaux Y., Zannad F., Regnault V., Lacolley P., Mertes P.M., Hess K., Longrois D. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb. Haemost. 2008, 99:558-569.
21. Schneeweis C., Gräfe M., Bungenstock A., Spencer-Hänsch C., Fleck E., Goetze S. Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration. J. Atheroscler. Thromb. 2010, 17:203-212.
22. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., Hawkins P.N., Myers R.M., Smith M.D., Polara A., Cobb A.J., Ley S.V., Aquilina J.A., Robinson C.V., Sharif I., Gray G.A., Sabin C.A., Jenvey M.C., Kolstoe S.E., Thompson D., Wood S.P. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217-1221.
23. Walsh S., Ponten A., Fleischmann B.K., Jovinge S. Cardiomyocyte cell cycle control and growth estimation in vivo - an analysis based on cardiomyocyte nuclei. Cardiovasc. Res. 2010, 86:365-373.
24. Barile L., Chimenti I., Gaetani R., Forte E., Miraldi F., Frati G., Messina E., Giacomello A. Cardiac stem cells: isolation, expansion and experimental use for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:S9-S14.
25. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., Ishino K., Ishida H., Shimizu T., Kangawa K., Sano S., Okano T., Kitamura S., Mori H. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 2006, 12:459-465.
26. Zeng L., Hu Q., Wang X., Mansoor A., Lee J., Feygin J., Zhang G., Suntharalingam P., Boozer S., Mhashilkar A., Panetta C.J., Swingen C., Deans R., From A.H., Bache R.J., Verfaillie C.M., Zhang J. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 2007, 115:1866-1875.
27. Ahuja P., Sdek P., MacLellan W.R. Cardiac myocyte cell cycle control in development, disease and regeneration. Physiol. Rev. 2007, 87:521-544.
28. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
29. Blaschke F., Bruemmer D., Yin F., Takata Y., Wang W., Fishbein M.C., Okura T., Higaki J., Graf K., Fleck E., Hsueh W.A., Law R.E. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004, 110:579-587.
30. Kitsis R.N., Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N. Eng. J. Med. 2006, 55:513-515.
31. Achanta G., Pelicano H., Feng L., Plunkett W., Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogs: potential role as a sensor complex for DNA damage. Cancer Res. 2001, 61:8723-8729.
32. Tritarelli A., Oricchio E., Ciciarello M., Mangiacasale R., Palena A., Lavia P., Soddu S., Cundari E. P53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol. Biol. Cell 2004, 15:3751-3757.
33. Okuno T., Matsuoka M., Sumizawa T., Igisu H. Involvement of the extracellular signal-regulated protein kinase pathway in phosphorylation of p53 protein and exerting cytotoxicity in human neuroblastoma cells (SH-SY5Y) exposed to acrylamide. Arch. Toxicol. 2006, 80:146-153.
34. Liu J., Mao W., Ding B., Liang C.S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1956-H1965.
35. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 2005, 117:104-111.
36. Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004, 109:1955-1959.